A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
This is a Phase I study designed to test the safety and tolerability of a cancer vaccine regimen consisting of the peptide conjugate SVN53-67/M57-KLH in Montanide ISA 51 given subcutaneously together with GM-CSF, given before or after lenalidomide (Len) maintenance in multiple myeloma patients who achieved at least a partial response after initial induction therapy.
Study Number: 

I 247913

Early Phase
Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.